ClinicalTrials.gg
RecruitingNCT05686759Updated Jun 25, 2025

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

A Phase 3 interventional study of Undiluted I.V.-Hepabig inj(GC5103) and Diluted I.V.-Hepabig inj(GC5103) in Hepatitis B, sponsored by GC Biopharma Corp. Recruiting at 8 sites in South Korea. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by GC Biopharma Corp · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Hepatitis B with a site in Korea, Republic of — 3 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B · Korea, Republic of.

Planned enrollment
25th of 70
105 · median 80
Started
2023
with 2 others
Phase 3
13 of 76
1 open now
Registered
70th of 76
by date

Among the 76 studies in Hepatitis B with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 in phase 3, and was the 70th registered.

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 76 studies in Hepatitis B with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hepatitis B with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients

03

Conditions studied

  • Hepatitis B

Keywords

  • Hepatitis B
  • Liver Transplantation
  • Hepatitis B Immunoglobulin
  • Liver Diseases
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 and \<65 years at the time of signing the consent form
  2. Subjects who had history of liver transplantation due to -related end-stage liver disease such as cirrhosis, liver cancer and fulminant hepatic failure and received treatment for prevent hepatitis B recurrence
  3. HBsAg(+) before liver transplantation
  4. Subjects who have been received I.V.-Hepabig inj more than 3 times dose of 10,000International Unit/4weeks regimen

Exclusion criteria

Exclusion Criteria:

  1. Subject with history of anaphylaxis to any component of the product
  2. Pregnant or breast-feeding women
  3. Deficiency of Immunoglobulin A
  4. renal diseases (serum creatinine >2.0mg/dL, anuria, renal failure or on dialysis at screening)
  5. Hemophilia
  6. Co-infection with Hepatitis A Virus, Virus, or
  7. Subject with history of within the last 5 years (excluding primary liver cancer)
  8. Subject received estrogen or hormone replacement therapy within 3 months before screening
  9. or HBeAg or HBV DNA positive at screening
  10. Anti HBs titer less than below criteria at screening \<150 IU/L for subject whose HBeAg and HBV DNA were negative(-) before liver transplantation >500 IU/L for subject whose HBeAg or HBV DNA were positive(+) before liver transplantation
  11. Subject with history of drug abuse
  12. Participated in another clinical study within 30 days (relative to the last dose of investigational product) before screening
  13. Subject who are determined disqualified to join clinical trials by investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Undiluted intravenous infusion of I.V.-Hepabig inj

    Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes

    Biological: Undiluted I.V.-Hepabig inj(GC5103)

  • Active comparator
    Diluted intravenous infusion of I.V.-Hepabig inj

    Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour

    Biological: Diluted I.V.-Hepabig inj(GC5103)

Interventions

  • BiologicalUndiluted I.V.-Hepabig inj(GC5103)

    undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

  • BiologicalDiluted I.V.-Hepabig inj(GC5103)

    Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

06

What researchers measure

Primary outcomes

  1. Adverse events occurred during clinical trials

    Safety will be assessed throughout the study through clinical safety evaluations(Adverse events)

    Time frame: during 20 weeks post first Investigational product administration

Secondary outcomes

  1. Positive rate of Hepatitis B Surface Antigen(HBsAg)

    Hepatitis B Surface Antigen(HBsAg) will be tested at every visit(V1\~V7)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  2. Hepatitis B Surface Antibody(Anti HBs) titer

    Hepatitis B Surface Antibody(Anti HBs) titer will be tested at every visit(V1\~V7)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  3. Positive rate of Hepatitis B e Antigen(HBeAg)

    Hepatitis B e Antigen(HBeAg) will be tested at every visit(V1\~V7)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  4. Positive rate of Hepatitis B Virus DNA(HBV DNA)

    Hepatitis B Virus DNA(HBV DNA) will be tested at every visit(V1\~V7)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  5. Laboratory tests

    Change from baseline in safety laboratory tests results (hematology,chemistry, urine) (each visit)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  6. Vital signs

    Change from baseline in vital sign (Blood Pressure, Pulse Rate, Body Temperature) (each visit)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

  7. Physical examination

    Change from baseline in physical examination (Appearance, Skin, Head/Neck, Thorax/Lungs etc) (each visit)

    Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 38 months after the start.

Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 38 months is above that.

Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Jan 17, 2023
StartActual
Apr 13, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05686759
Lead sponsor
GC Biopharma Corp
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Apr 13, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 25, 2025

Study contacts

Jiyoung Sin
Contact
jiyoung.sin@gccorp.com
82-(0)31-260-9570

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion